Sean S O'Connell

age ~69

from South Boston, MA

Get Report

Also known as:

Sean Steven O'Connell

Phone and address:: 708 E 7Th St, Boston, MA 02127
(617)2686342

Connected to:

Sean O'Connell Phones & Addresses

708 E 7Th St, South Boston, MA 02127 • (617)2686342
Boston, MA
Malden, MA
Weymouth, MA

Lawyers & Attorneys

Sean O'Connell - Lawyer

view source

ISLN:

923364708

Admitted:

2013

License Records

Sean P O'connell

Address:

Brighton, MA 02135

License #:

3026 - Expired

Issued Date:

Oct 21, 2015

Expiration Date:

Jan 31, 2017

Type:

Landscape Architect

Resumes

Sean O'connell North Chelmsford, MA

view source

Work:

LAER Real Estate Partners/ZipRealty, Inc.

Jun 2013 to 2000
Licensed Realtor/Sales Agent PepsiCo
Canton, MA
Sep 1999 to Jun 2013
Account Sales Manager Pepsi Cola
Wilmington, MA
Jun 1994 to Sep 1999
Bulk Service Merchandiser

Education:

University of Massachusetts/Lowell
Lowell, MA
1992 to 1997
BA in Liberal Arts/History

Sean O'connell Abington, MA

view source

Work:

SRO Companies LLC
Kingston, MA
Jun 2007 to Aug 2012
Project Manager / Operations Manager SRO Companies LLC

2007 to 2009
Project Manager / Project Estimator Caliper Woodworking
Malden, MA
2002 to 2007
Head of estimating department SRO Companies LLC

Lead Project Manager

Education:

Northeastern University
Boston, MA
2002 to 2004
Certificate in Construction Management / Facilities Management Northeastern University
Boston, MA
2002 to 2004
Certificate in Construction Management / Facilities Management in Construction Project Management. Facilities Management Wentworth Institute Of technology
Boston, MA
2002 to 2004
Certificate In Massachusetts Building Codes in Construction Management

Skills:

Hands on site superintendent. OSHA 30 and 10 hour with endorsements in Asbestos.Confinded Space RESCUE 2013 Cranes, Confined Space,Excavation, HAZWOPER

Sean O'connell Abington, MA

view source

Work:

SRO Companies LLC

Jun 2007 to Oct 2012
Lead Project Manager Caliper Woodworking
Malden, MA
2006 to 2007
Project Manager and Head of Estimating Department Gloucester Builders INC
Charlestown, MA
2004 to 2006

Education:

Wentworth Institute of Technology
Boston, MA
Jan 2002 to Jan 2004
Certificate in Construction Supervision Northeastern University
Boston, MA
2002 to 2004
Certificate in Construction Management / Facilities Management

Skills:

Corporate Safety Policy Team. Proficient in MS Office programs. Extensive corporate travel experience. Relocation coordination. Meeting coordination.

Us Patents

Method For Controlling Viral Infections Through Adoptive Transfer Of A Cell Product Comprising An Expanded And Enriched Population Of Superactivated Cytokine Killer Cells
view source
US Patent:

20220401477, Dec 22, 2022
Filed:

May 17, 2022
Appl. No.:

17/746307
Inventors:

- Houston TX, US
Lilit Garibyan - Newton MA, US
Beverly W. Lubit - Kinnelon NJ, US
Sean O'Connell - Budd Lake NJ, US
Assignee:

VERDURE BIOTECH, INC. - Houston TX
International Classification:

A61K 35/17
A61P 37/04
Abstract:

The invention of the present disclosure provides a method for treating a viral infection in a recipient subject suffering from or at risk of a viral infection including administering to the recipient subject a pharmaceutical composition comprising a therapeutic amount of superactivated cytokine killer T cells (SCKTCs) and a pharmaceutically acceptable carrier, and mobilizing an immune response of the recipient subject to the viral pathogen. When tested in vitro, the SCKTCs are characterized by a predominant production of T1 dominant cytokines including IFN-γ; an IFN-γ:IL-4 ratio of at least 500:1; and at least 50% killing of target A549 cells at an effector:target ratio of 20:1. The present disclosure further provides a method of preparing a pharmaceutical composition comprising an enriched population of superactivated cytokine killer T cells (SCKTCs) wherein pulsing steps with monocyte-derived dendritic cells (DCs) loaded with alpha-GalCer achieve at least an 80% pure population of SCKTCs without positive or negative cell separation methods.

Universal Vaccines Against Immunogens Of Pathogenic Organisms That Provide Organism-Specific And Cross-Group Protection
view source
US Patent:

20220249651, Aug 11, 2022
Filed:

Jan 31, 2022
Appl. No.:

17/589484
Inventors:

- Coral Springs FL, US
Lilit Garibyan - Newton MA, US
Helen Hao - Piscataway NJ, US
Sean O'Connell - Budd Lake NJ, US
Assignee:

AEGLE BIOTECH - Coral Springs FL
International Classification:

A61K 39/145
A61P 31/16
C07K 14/005
C12N 15/86
C12N 7/00
Abstract:

The present disclosure provides, in part, a priming and boosting vector-based platform to develop vaccines against viral pathogens that is tailored to elicit a broad T cell response targeting conserved viral epitopes while including helper T cell (T) epitopes and an adjuvant to achieve a balanced immune response consisting of both cellular immunity, coupled with a broad neutralizing antibody response in the design of a candidate universal vaccine to HIV or a human coronavirus, e.g., SARS-CoV-2. The universal vaccines are prepared against an immunogen of an infectious pathogenic virus comprising at least one nucleic acid polynucleotide comprising an open reading frame encoding at least one polypeptide antigen or an immunogenic fragment thereof, wherein the polypeptide antigen, or the immunogenic fragment thereof, comprises a conserved internal protein that is enriched in T cell recognition antigens. The effectiveness of the priming and boosting platform is tested in humanized mouse models: a transgenic mouse model that expresses the hACE2 gene under the control of the human cytokeratin 18 promoter and a humanized mouse model comprising a fully functional human immune system.